TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8387346
Drug: Chemotherapy preceded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy preceded and followed by rhGM‐CSF (days -17 to -7 for priming, days 4-14 for rescue)
Study: 8387346
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus rhGM‐CSF rescue
Study: 8387346
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by rhGM‐CSF
Study: 8387346
Drug: Chemotherapy preceded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy preceded and followed by rhGM‐CSF
Study: 3523796
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg plus hydrochlorothiazide 12.5 mg (SDX)
Study: 9366100
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg (HCT)
Study: 18665167
Drug: Irinotecan 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg m‐2 and cetuximab 500 mg m‐2 q2w
Study: 20813681
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Lornoxicam (L8 group)
Study: 20813681
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg Lornoxicam (L16 group)
Study: 20813681
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml saline (NS group)
Study: 11897411
Drug: Intranasal powder
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal powder form of glucagon mixed with microcrystalline cellulose at a ratio of 1:69
Study: 11897411
Drug: Spray solutions
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray solutions of glucagon including 1.5% sodium glycocholate
Study: 11897411
Drug: Spray solutions
Normalized name: Inhalation Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray solutions of glucagon including 1% sodium caprate
Study: 9600795
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg/day
Study: 9600795
Drug: Clodronate 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 2400 mg/day
Study: 9600795
Drug: Clodronate 800
Normalized name: clodronic acid 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 800 mg/day
Study: 8027622
Drug: Adjuvant intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant intraperitoneal 5‐fluorouracil (5‐FU, 500 mg/m2/day) and intravenous leucovorin (60 mg/m2/day)
Study: 2731750
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g qds (n = 24)
Study: 2731750
Drug: cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 200 mg tds and 400 mg nocte (n = 22)
Study: 2731750
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g bd during maintenance
Study: 2731750
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg nocte during maintenance
Study: 790548
Drug: Ketoprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (150 mg daily in 3 doses of 50 mg)
Study: 30690446
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen (CEE) plus 100 mg micronized progesterone (MP)
Study: 30690446
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg CEE daily plus 100 mg MP
Study: 30690446
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg CEE daily plus 10 mg dydrogesterone (DHG)
Study: 29505549
Drug: Intralipid postconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid postconditioning (ILPC) - intravenous infusion of 20% intralipid (2 mL/kg) just 10 minutes before aortic cross-unclamping
Study: 25012422
Drug: 0.25mg oral
Normalized name: Digoxin 0.25mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg oral haloperidol daily for 7 days, followed by placebo for 4 weeks
Study: 22724108
Drug: Nonthermal atmospheric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonthermal atmospheric pressure plasma (APP) treatment
Study: 22724108
Drug: Nonthermal atmospheric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonthermal atmospheric pressure plasma (APP) treatment at the highest input voltage
Study: 15777444
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (no cervical priming agent)
Study: 12452759
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of salmeterol to low-dose fluticasone propionate
Study: 12452759
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose of fluticasone propionate
Study: 8803398
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent carbamide peroxide gel
Study: 8926595
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bisoprolol once daily for three weeks
Study: 2046107
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (antihypertensive drug treatment with chlorthalidone and atenolol)
Study: 6786204
Drug: Estrogen at
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen at half the treatment dose
Study: 30885242
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl through 48 h postsurgery
Study: 27913279
Drug: Higher abrasivity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher abrasivity daily-use whitening dentifrice
Study: 27129124
Drug: Enalapril oral
Normalized name: enalapril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril oral solution (1 mg/mL)
Study: 27129124
Drug: Enalapril oral
Normalized name: enalapril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril oral solution with a high-fat meal
Study: 27129124
Drug: Reference listed
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference listed drug (RLD) tablet
Study: 19718777
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) administration
Study: 17043680
Drug: Oral Delta(9)-tetrahydrocannabinol
Normalized name: delta 9-tetrahydrocannabinol acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Delta(9)-tetrahydrocannabinol (THC)
Study: 17043680
Drug: Rectal THC-hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal THC-hemisuccinate (THC-HS)
Study: 12506472
Drug: cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin (CDDP) 5 mg/body/day (i.v.) plus 5‐FU 300 mg/body/day (cvi) day 1‐5 for 6 weeks, followed by UFT 200 mg (as tegafur) x 2/day for as long as possible
Study: 12506472
Drug: UFT only
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT only administered after surgery as long as possible
Study: 9719743
Drug: Methylprednisolone 30
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 30 mg/kg intravenously 90 minutes prior to induction of anaesthesia (group 1)
Study: 8573222
Drug: Pentalong 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentalong 50 mg tablets (2 tablets per dose)
Study: 8573222
Drug: Aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension prepared from 25% PETN/lactose trituration
Study: 7759705
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg body weight over 15 min)
Study: 2809002
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 ml of saline solution over 15 min)
Study: 7636050
Drug: SCH 434
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 434 QD (10 mg loratadine + 240 mg pseudoephedrine sulfate)
Study: 31037454
Drug: Slower rate
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower rate of infusion of etomidate
Study: 31037454
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction dose of etomidate
Study: 2801064
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low dose heparin (5.000 IU) and dihydroergotamine (0.5 mg) given subcutaneously every twelve hours (n = 27)
Study: 27632530
Drug: Computer-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based training program (special nonsense-syllables with background noise), 3 weeks, twice a week for 1 hour
Study: 22682547
Drug: Alpha adrenergic
Normalized name: Alpha adrenergic receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha adrenergic blockers
Study: 19724889
Drug: Glucosamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine administration (1.5 g and 3 g/day for 3 months)
Study: 17179022
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg oral dose)
Study: 11765110
Drug: Obstacles to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstacles to implementing pharmaceutical care programs
Study: 31603191
Drug: Personalized antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antiplatelet therapy (according to maximum aggregation rate); if MAR > 55%, 90 mg ticagrelor twice daily plus 100 mg/day aspirin; if MAR ≤ 55%, 75 mg/day clopidogrel plus 100 mg/day aspirin
Study: 31603191
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet treatment (75 mg/day clopidogrel plus 100 mg/day aspirin for at least 6 months)
Study: 31603191
Drug: Personalized antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized antiplatelet therapy
Study: 31242860
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B deoxycholate 0.7-1.0 mg/kg/day for induction therapy
Study: 31242860
Drug: Strategies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies to minimize/prevent phlebitis: 1 liter of IV normal saline after each dose, rotating IV catheters every three days, infusing IV amphotericin over 4 hours, encouraging early ambulation
Study: 31242860
Drug: Warm compresses,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm compresses, topical diclofenac gel, and oral anti-inflammatory medicines for severe cases
Study: 25955443
Drug: Mitii (web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitii (web-based therapy programme) for 20 weeks
Study: 17940371
Drug: Neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation therapy
Study: 15294364
Drug: Dinoprostone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (0.5 mg intracervically every 6 h)
Study: 11514956
Drug: Highly Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Active Antiretroviral Therapy (HAART)
Study: 9569468
Drug: Five-component pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-component pertussis combination vaccine (CPDT‐IPV//PRP‐T)
Study: 9569468
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection of CPDT‐IPV and PRP‐T
Study: 9569468
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis combination vaccine (DPT‐IPV//PRP‐T)
Study: 9569468
Drug: Component vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component vaccines (CPDT‐IPV)
Study: 9569468
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell vaccine (DPT‐IPV)
Study: 3410154
Drug: Salbutamol administered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol administered from the Diskhaler (breath operated system)
Study: 3410154
Drug: Salbutamol administered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol administered from the metered dose inhaler
Study: 27038550
Drug: Differential Depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differential Depression Treatment Response Index (DTRI)
Study: 27038550
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers (DNA, RNA, plasma)
Study: 27038550
Drug: Biological moderators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological moderators and mediators
Study: 24714008
Drug: Crystalloid/colloid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid/colloid combination (750 ml crystalloid and 250 ml colloid)
Study: 24714008
Drug: Colloid intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid intravenous fluid preload (500 ml)
Study: 21404369
Drug: Methylphenidate combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate combined with multimodal behaviour therapy
Study: 19400874
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 100 mg/day
Study: 19400874
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 mg/day
Study: 17334460
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 2 mg/kg (Group K)
Study: 17334460
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol 3 mg/kg and intravenous fentanyl 1 microg/kg with propofol infusion of 1 mg/kg/hr (Group PF)
Study: 15166683
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg/dose, twice a day)
Study: 11777112
Drug: No-treatment comparison
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment comparison group
Study: 9775459
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) phenobarbital 10 micrograms/kg (n = 42 newborns)
Study: 27016000
Drug: BG00010 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG00010 (50, 150, 400, 800 μg kg(‐1) in Part I; 400, 600, 1200 μg kg(‐1) in Part II)
Study: 18801405
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid)
Study: 15959636
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear treatment for at least 6 months achieving a minimum distalization of 4 mm
Study: 28455746
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear treatment
Study: 15314975
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who had not undergone inductive chemotherapy)
Study: 10894097
Drug: Talc slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc slurry (5 grams mixed in 150 mL of normal saline)
Study: 10894097
Drug: Bleomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin (1 unit per kilogram bodyweight mixed in 150 mL of normal saline)
Study: 8895044
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg capsules once daily for 3 days)
Study: 8895044
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg tablet three times daily for 5-10 days)
Study: 8457082
Drug: Calcium-heparin (12,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-heparin (12,500 IU/day, subcutaneous)
Study: 8457082
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg/day, oral)
Study: 24470701
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia (CBT-I), 4-week group-administered program
Study: 19902183
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of rimonabant for 2 weeks
Study: 18049294
Drug: Methylphenidate 5
Normalized name: dexmethylphenidate 5.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 5 mg twice daily
Study: 18049294
Drug: Methylphenidate 10
Normalized name: dexmethylphenidate 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 10 mg twice daily
Study: 18049294
Drug: Methylphenidate 15
Normalized name: METHYLPHENIDATE 15MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 15 mg twice daily
Study: 10519608
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group)
Study: 10519608
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group)
Study: 10519608
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group) in patients with non-persistently high basal FSH
Study: 10519608
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group) in patients with non-persistently high basal FSH
Study: 8480681
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (900 mg/d for 4 mo)
Study: 1105627
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 or 20 mg)
Study: 1105627
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 or 0.2 mg)
Study: 27096396
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement treatment
Study: 19495810
Drug: Self-management treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management treatment
Study: 25105516
Drug: GS-9620 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (0.3, 1, 2 and 4 mg)
Study: 25105516
Drug: GS-9620 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (1, 2 and 4 mg)
Study: 21428241
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg (test formulation)
Study: 21428241
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg (reference formulation)
Study: 19231325
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (medical treatment)
Study: 16987370
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg followed by 50 microg/kg/min)
Study: 14692166
Drug: Tooth-whitening gel
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night in addition to a commercially available dentifrice.
Study: 14692166
Drug: Tooth-whitening gel
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night.
Study: 8113493
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training therapy
Study: 30169192
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 3 μg/kg
Study: 30169192
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 3 μg/kg (in boys)
Study: 25506618
Drug: Motor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor therapy focusing on the nonparetic side along with the conventional program
Study: 8709183
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and IVGG 400 mg/kg/day for 5 consecutive days
Study: 8709183
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours
Study: 31014147
Drug: Dexmedetomidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine treatment group (n=25)
Study: 29785101
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg once-daily maintenance therapy
Study: 24700398
Drug: CC/Gn/GnRH‐ant 'mild'
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC/Gn/GnRH‐ant 'mild' protocol
Study: 24700398
Drug: GnRH‐agonist and
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐agonist and high‐dose Gn 'long' protocol
Study: 17459013
Drug: Self-reported willingness-to-pay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported willingness-to-pay (WTP) for a theoretical treatment with a cure rate of 85%
Study: 15226331
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m² on days 1 through 5, four cycles, every 3 weeks)
Study: 11343045
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg added to budesonide 200 microg twice daily